Gastrointestinal candidiasis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:54:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastrointestinal candidiasis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Rezafungin in Blood and Peritoneal Fluid for Patients with Suspected Intra-Abdominal Candidiasis https://clinicaltrials.eu/trial/study-of-rezafungin-in-blood-and-peritoneal-fluid-for-patients-with-suspected-intra-abdominal-candidiasis/ Wed, 29 Apr 2026 15:07:31 +0000 https://clinicaltrials.eu/trial/study-of-rezafungin-in-blood-and-peritoneal-fluid-for-patients-with-suspected-intra-abdominal-candidiasis/ This study focuses on patients with Intra-Abdominal Candidiasis, which is a fungal infection that occurs inside the abdomen. The research examines a medication called Rezafungin, which is given through intravenous infusion (delivered directly into a vein). This medicine belongs to a group of drugs used to treat fungal infections.

The study aims to understand how Rezafungin spreads through the body, particularly how it moves between the blood and the fluid in the abdomen. The medication will be given to patients who have signs of infection in their abdomen that hasn’t improved with other treatments. Patients will receive the medicine through an infusion into their vein, and samples will be collected from both their blood and abdominal fluid.

During the study, doctors will monitor how well the medication works against common types of fungi, specifically Candida albicans and Candida glabrata. They will also track the patients’ recovery and any changes in their condition. The treatment period may last up to 4 weeks, during which various measurements and observations will be made to evaluate the effectiveness of the medication.

]]>